A detailed history of Engineers Gate Manager LP transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Engineers Gate Manager LP holds 5,038 shares of BMRN stock, worth $410,345. This represents 0.01% of its overall portfolio holdings.

Number of Shares
5,038
Holding current value
$410,345
% of portfolio
0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$83.81 - $99.0 $422,234 - $498,762
5,038 New
5,038 $440,000
Q2 2023

Aug 14, 2023

BUY
$86.68 - $100.3 $838,022 - $969,700
9,668 Added 122.24%
17,577 $1.52 Million
Q1 2023

May 15, 2023

SELL
$87.74 - $117.27 $874,855 - $1.17 Million
-9,971 Reduced 55.77%
7,909 $769,000
Q4 2022

Feb 14, 2023

SELL
$80.93 - $108.63 $1.76 Million - $2.37 Million
-21,797 Reduced 54.94%
17,880 $1.85 Million
Q3 2022

Nov 14, 2022

BUY
$82.16 - $96.94 $2.16 Million - $2.55 Million
26,262 Added 195.77%
39,677 $3.36 Million
Q2 2022

Aug 15, 2022

BUY
$71.48 - $86.85 $958,904 - $1.17 Million
13,415 New
13,415 $1.11 Million
Q4 2021

Feb 14, 2022

SELL
$71.72 - $91.47 $253,960 - $323,895
-3,541 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$74.77 - $85.47 $70,358 - $80,427
941 Added 36.19%
3,541 $274,000
Q2 2021

Aug 16, 2021

SELL
$75.51 - $84.79 $1 Million - $1.13 Million
-13,275 Reduced 83.62%
2,600 $217,000
Q1 2021

May 17, 2021

BUY
$74.73 - $90.69 $586,779 - $712,097
7,852 Added 97.87%
15,875 $1.2 Million
Q4 2020

Feb 16, 2021

BUY
$72.61 - $90.2 $582,550 - $723,674
8,023 New
8,023 $704,000
Q4 2019

Feb 14, 2020

SELL
$64.27 - $86.37 $2.49 Million - $3.34 Million
-38,705 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$67.4 - $85.11 $627,157 - $791,948
9,305 Added 31.65%
38,705 $2.61 Million
Q2 2019

Aug 14, 2019

BUY
$80.35 - $93.9 $2.36 Million - $2.76 Million
29,400 New
29,400 $2.52 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $15.1B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.